Get the Stockscreener App
226.08
1.15%
-2.63
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $226.08, with a volume of 3.94M.
It is down -1.15% in the last 24 hours and up +4.29% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$228.71
Open:
$228.93
24h Volume:
3.94M
Relative Volume:
0.67
Market Cap:
$399.57B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
170.59
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
-0.71%
1M Performance:
+4.29%
6M Performance:
+20.60%
1Y Performance:
+28.33%
1-Day Range:
$225.05
$229.25
1-Week Range:
$223.11
$230.94
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
226.08 | 404.22B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,010.31 | 907.99B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
201.93 | 487.83B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
132.16 | 254.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.72 | 250.41B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) - GlobeNewswire Inc.
AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer - PR Newswire
Is AbbVie Inc. (4AB) stock undervalued after correctionWeekly Trade Summary & Community Consensus Picks - Newser
How Strong Is AbbVie's Immunology Franchise After Humira's LOE? - The Globe and Mail
Could buying AbbVie today set you up for life? - MSN
Could Buying AbbVie Today Set You Up for Life? - Nasdaq
Dry Eye Disease Treatment Market Outlook Report 2032 | Alcon - openPR.com
Why AbbVie Inc. stock attracts global investorsMarket Performance Summary & Fast Exit and Entry Strategy Plans - Newser
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts - ts2.tech
Assessing AbbVie’s (ABBV) Valuation After New Cancer Data, EPKINLY Approval, and Dividend Hike - simplywall.st
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Dermal Fillers Market Size Report 2032 | AbbVie Inc., Galderma, - openPR.com
AbbVie looks to expand use cases for migraine drug after promising study - Crain's Chicago Business
Invesco Ltd. Lowers Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Is AbbVie Inc. stock undervalued at current priceSwing Trade & Weekly High Conviction Ideas - Newser
AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook - ts2.tech
Metastatic Non-Small Cell Lung Cancer Market on Track for Major Expansion by 2034, According to DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics - Barchart.com
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73 - simplywall.st
AbbVie to feature new data at ASH 2025 - MarketScreener
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers - Investing News Network
AbbVie (NYSE: ABBV) highlights ASH 2025 advances in T-cell engagers, BCL-2 and ADCs - Stock Titan
2 Top Dividend Stocks to Buy Now and Hold For a Decade - AOL.com
Portfolio Design Labs LLC Has $571,000 Stake in AbbVie Inc. $ABBV - MarketBeat
Shelton Capital Management Has $7.29 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Loomis Sayles & Co. L P Purchases 18,866 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Fisher Asset Management LLC - MarketBeat
AbbVie (ABBV) Faces New Generic Competition for Restasis - GuruFocus
Willis Johnson & Associates Inc. Decreases Holdings in AbbVie Inc. $ABBV - MarketBeat
If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
Sepio Capital LP Has $38.93 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie: Increased Outlook For 2025 And Expansions Merit Continued 'Strong Buy' Rating - Seeking Alpha
AbbVie Inc. $ABBV is Distillate Capital Partners LLC's 4th Largest Position - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Everstar Asset Management LLC - MarketBeat
Edgestream Partners L.P. Takes $12.43 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress - PR Newswire
BLI Banque de Luxembourg Investments Has $1.82 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets - ts2.tech
AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.73 - Yahoo Finance
AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength - ts2.tech
Aug Final Week: How cyclical is AbbVie Inc. stock compared to rivalsDip Buying & Capital Efficiency Focused Strategies - moha.gov.vn
3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years - Finviz
AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate - ts2.tech
Total liabilities & shareholders' equities of AbbVie, Inc. – SIX:ABBV - TradingView
Assessing AbbVie’s (ABBV) Valuation: Is There More Upside After Recent Performance? - Yahoo Finance
ABBVAbbvie Inc Stock Price and Quote - Finviz
SKYRIZI® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - Investing News Network
AbbVie (ABBV) Gains Canadian Support for Ulcerative Colitis Trea - GuruFocus
AbbVie Announces Positive Reimbursement Recommendations for SKYRIZI® in Ulcerative Colitis by Canada's Drug Agency - Quiver Quantitative
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - MarketScreener
3 Dividend-Paying Stocks that Are Up Over 30% in 2025 - Tokenist
AbbVie Unit Fails To Revive Dermal Filler Patent On Appeal - Law360
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):